Familial hypercholesterolemia in China half a century: A review of published literature

Peng, Jie; Wu, Xiao Qing; Wang, Shilong; Zhang, Shuang; Wang, Xumin; Liu, Zesen; Hong, Jing; Ye, Pucong; Lin, Johnson

doi:10.1016/j.atherosclerosissup.2019.01.003

Cited by 9 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study also demonstrated that the prevalence of FH in older participants was higher than younger participants. Moreover, a review of FH has illustrated that age was linked with the increased risk of coronary artery disease among Chinese FH patients [12]. Importantly, early and timely detection of FH among children and young adults for the prevention of premature cardiovascular disease was urgently needed.…”

Section: Discussionmentioning

confidence: 99%

“…Studies have shown that large-scale epidemiological investigations in China about FH are still scarce. There exist gaps between China and international community about Registry system and national management of FH [12, 13]. This phenomenon motivates studies to explore the prevalence in large-scale unselected population in more Chinese regions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The prevalence and related factors of familial hypercholesterolemia in rural population of China using Chinese modified Dutch Lipid Clinic Network definition

Wang

Liu

et al. 2019

BMC Public Health

View full text Add to dashboard Cite

Background Familial hypercholesterolemia (FH) is a common monogenic disease, while studies about the epidemiology for the general population in China was scarce. Aim of the study was to estimate the prevalence of FH and explore related factors by the Chinese modified Dutch Lipid Clinic Network (DLCN) definition. Methods A total of 39,205 participants (15,463 males and 23,742 females) aged 18–79 years old were enrolled from the Henan Rural Cohort Study. FH was defined by the Chinese modified DLCN definition, and score > 5 was classified as FH. Logistic regression analysis was used to calculate the odds ratio and 95% confidence interval. Results Crude prevalence of probable/definite FH was 0.35% (0.29–0.41%), estimated by the Chinese modified DLCN definition. Prevalence in female was 0.38%, and in male, it was 0.32%. Age-standardized prevalence in female increased significantly around the age of 50 years. Moreover, there were no FH patients getting low-density lipoprotein cholesterol controlled to the recommended level. Multivariate logistic regression identified that older, overweight/obesity were positively associated with FH. Conclusions The current study indicated that FH was not rare in rural area of China (1 in 286). Effective early detection and timely control of FH must be strengthened to reduce disease burden. Electronic supplementary material The online version of this article (10.1186/s12889-019-7212-4) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The prevalence and related factors of familial hypercholesterolemia in rural population of China using Chinese modified Dutch Lipid Clinic Network definition

Wang

Liu

et al. 2019

BMC Public Health

View full text Add to dashboard Cite

show abstract

“…Less than 1% of Chinese patients with FH were diagnosed or treated before 2018 because there were no standard diagnosis criteria for FH in China until 2018 and Chinese patients usually present with lower levels of cholesterol than thresholds based on the western population [ 47 , 51 ]. Among Chinese patients with FH, mutations in LDL receptor are most common (82%), followed by mutations in apolipoprotein B (9%) [ 52 ]. The underdiagnosis of FH (< 10%) is also an issue in most high-income countries including the US where genetic testing is not widely used [ 53 ].…”

Section: Methodsmentioning

confidence: 99%

Landscape of cardiometabolic risk factors in Chinese population: a narrative review

Liu

2022

Cardiovasc Diabetol

View full text Add to dashboard Cite

With rapid economic growth and changes at all levels (including environmental, social, individual), China is facing a cardiovascular disease (CVD) crisis. In China, more than 40% of deaths are attributable to CVDs, and the number of CVD deaths has almost doubled in the past decades, in contrast to a decline in high-income countries. The increasing prevalence of cardiometabolic risk factors underlies the rise of CVDs, and thus curbing the rising cardiometabolic pandemic is imperative. Few articles have addressed this topic and provided an updated review of the epidemiology of cardiometabolic risk factors in China.In this narrative review, we describe the temporal changes in the prevalence of cardiometabolic risk factors in the past decades and their management in China, including both the well-recognized risk factors (general obesity, central obesity, diabetes, prediabetes, dyslipidemia, hypertension) and the less recognized ones (hyperhomocysteinemia, hyperuricemia, and high C-reactive protein). We also summarize findings from landmark clinical trials regarding effective interventions and treatments for cardiometabolic risk factors. Finally, we propose strategies and approaches to tackle the rising pandemic of cardiometabolic risk factors in China. We hope that this review will raise awareness of cardiometabolic risk factors not only in Chinese population but also global visibility, which may help to prevent cardiovascular risk.

show abstract

“…The mutation frequency was 82% in LDLR , 9% in APOB , and very rare in PCSK9 . The study concluded that the epidemiological investigation of FH was not large-scale, FH recognition remained rudimentary, and guidelines for diagnosis and management of FH patients were incomplete in China ( Peng et al, 2019 ).…”

Section: Genetic Diagnosis Of Fh In Asiamentioning

confidence: 99%

Genetic Diagnosis of Familial Hypercholesterolemia in Asia

Huang

Charng

2020

Front. Genet.

View full text Add to dashboard Cite

Familial hypercholesterolemia (FH) is a common genetic disease with an incidence of about 1 in 200-500 individuals. Genetic mutations markedly elevate low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease (ASCVD) in FH patients. With advances in clinical diagnosis and genetic testing, more genetic mutations have been detected, including those in low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9), and so on. Globally, most FH patients remain undiagnosed, untreated, or inappropriately treated. Recently, there was a Global Call to Action by the Global Familial Hypercholesterolemia Community to reduce the health burden of FH. Asia, despite being the most populous continent with half of the global population, has low FH detection rates compared to Western countries. Therefore, we aimed to review the current status of FH genetic diagnosis in Asia to understand the gaps in FH diagnosis and management in this region.

show abstract

Familial hypercholesterolemia in China half a century: A review of published literature

Cited by 9 publications

References 35 publications

The prevalence and related factors of familial hypercholesterolemia in rural population of China using Chinese modified Dutch Lipid Clinic Network definition

The prevalence and related factors of familial hypercholesterolemia in rural population of China using Chinese modified Dutch Lipid Clinic Network definition

Landscape of cardiometabolic risk factors in Chinese population: a narrative review

Genetic Diagnosis of Familial Hypercholesterolemia in Asia

Contact Info

Product

Resources

About